PharmaTalkRadio

Conference Producer, Mark Scherzer, talks through what to expect at the upcoming Patients as Partners EU virtual conference taking place 24-25 January 2022. 

The 6th annual conference will bring together pharma, biotech, CROs and technologists to figure out how to advance patient involvement in medicines development. Experts from Novartis, Pfizer, Merck, EMD Serono, Janssen, Johnson & Johnson, GSK, Ipsen, UCB, Takeda, AbbVie, Noema Pharma, Gilead Sciences, and Pierre Fabre will gather with patient advocacy to address:

Outcome measures that matter most to patients  Patient Experience Data for regulatory submissionsCompliance barriers to advance patient involvementIncreasing diversity in clinical researchPatient involvement in Turkey and Eastern EuropeImpacting clinical research through carer InputPatient involvement in the design and execution of platform trialsPatient access to research through digital innovation

About the Episode:

How can artificial intelligence maintain the pace of clinical trials from the COVID-19 pandemic to bring therapeutics to patients faster? Suresh Katta, CEO and founder of Saama Technologies, sits down to discuss exactly how artificial intelligence can be utilized to design better trials from the start, reduce costs and benefit patients and pharma in the long run. 

 

Key Takeaways:

How to create broader adoption and change management of new technologiesCreating the best protocol design from the start, without pricey and time-consuming amendmentsHow AI can reduce costs, as well as timelines

About the Speaker:

Suresh Katta founded Saama Technologies in 1997, well before the collective global corporate conscience was aware of the extraordinary opportunities – and significant challenges – inherent in big data. He is a frequent contributor to industry publications and a featured speaker at industry conferences. He earned his M.S. in Computer Engineering at the University of Southwest Louisiana, and his B.S. in Electronics Engineering at the University of Bangalore.

 

For more information:

About disruptive innovations in clinical research, click here. 

For more information about PharmaTalk Radio, visit theconferenceforum.org.

About the Episode:

How can therapeutics like biologics and small molecule drugs evolve in their delivery? Finn Doyle, SVP and General Manager of ENHANZE® at Halozyme, sits down to discuss exactly how these innovative therapeutics can be delivered subcutaneously where they have previously only been administered via IV, the impacts of doing so, and the keys to successful drug delivery collaborations. 

Key Takeaways:

 How switching to a SC delivery model impacts patients, healthcare providers and drug development companies Keys to successful partnerships and collaborations How Halozyme's ENHANZE® technology enables the shift from IV to SC

About the Speaker:

Finn Doyle joined Halozyme in May of 2021 as the Senior Vice President and General Manager of ENHANZE®. She is responsible for overseeing Halozyme’s ENHANZE® drug delivery technology, including responsibility for the annual operating plan and long-term growth strategy for the franchise. Ms Doyle will oversee the alliance management, ENHANZE® business development, regulatory and safety, and project management functions within Halozyme. Ms Doyle received a B.S. in Biochemistry from Trinity College in Dublin (Dublin University) and a degree in International Business and Marketing Ireland and did postgraduate research at MIT/Harvard.

 

For more information:

About drug delivery and partnerships, click here. 

For more information about PharmaTalk Radio, visit theconferenceforum.org.

About the Episode:

What does the future of eyecare look like? How does a global company stay innovative? Listen to this podcast to hear Dr Xiao-Yu Song, Johnson & Johnson Vision, providing the latest information on J&J Vision's new products, and her approach to innovation. 

 

Key Takeaways:

 How to encourage innovation in a large, global company What the current and future eyecare needs are How Johnson & Johnson Vision is expanding and innovating their products, including a first-in-class drug delivery contact lens

About the Speaker:

Xiao-Yu Song is the Global Head of Research & Development for Johnson & Johnson's eye health business. She has overall R&D responsibility for new product development and life cycle management support as well as portfolio management and innovation governance across all platforms in Johnson & Johnson Vision. Xiao-Yu earned her Ph.D. in Biology from the University of North Carolina at Chapel Hill, her M.S. in Biochemistry and Medical Degree at China Medical University, and completed postdoctoral training in autoimmunity and immunology at the U.S. National Institutes of Health. 

 

For more information:

About disruptive innovation in clinical research, click here.

About drug delivery and partnerships, click here. 

For more information about PharmaTalk Radio, visit theconferenceforum.org.

About the Episode:

As the COVID-19 pandemic encourages the widespread adoption of decentralized clinical trial models, there are opportunities to optimize existing processes to make clinical research easier for sites and sponsors to conduct, and for patients to participate. Jonathan Andrus, Clinical Ink, discusses his advice as a flexible data collection expert, thoughts on wider adoption of DCTs and where he thinks the future is headed.

 

Key Takeaways:

The role of regulatory guidance, how-to's and industry examplesShifting from a "surviving" to "thriving" mentality in regards to DCTsNext steps for the industry

About the Speaker:

Jonathan Andrus is Chief Strategy Officer of Clinical Ink. He is responsible for driving the corporate strategic vision, communicating the plan with all those involved, executing the business initiatives, and sustaining implementation efforts. This includes driving important internal initiatives, identifying potential targets for acquisition, and other partnership opportunities to help drive the business forward.

About Mobile in Clinical Trials:

Mobile in Clinical Trials is the meeting place for digital R&D operations leaders who are seeking solutions to apply mobile-digital tools into clinical research.  Each year, we bring forward the latest experience-based case studies while presenting fresh ideas to advance fit for purpose, adoption and scale of remote digital solutions. For more information, click here.

For more information about PharmaTalk Radio, visit theconferenceforum.org.

While the idea that trust between sponsors and development partners is integral to success is well known, actually building that relationship requires real effort and empathy from both groups. Today, Dr Skip Sands, Senior Vice President and Senior Medical Officer of Parexel Biotech, discusses practical examples of how to build and maintain that relationship of trust and navigate challenges that arise based on his experience on both sides of the sponsor and CRO partnership.

 

Key takeaways:

How to choose the right development partnerBuilding the relationship infrastructure from the bid process through clinical developmentCommunicating and managing expectations between sponsors and CROs

 

Guest: Earl “Skip” Sands, MD, MBA, Senior Medical Officer, Parexel Biotech

Prior to joining Parexel Biotech as Senior Medical Officer in 2019, Dr Sands served as the Chief Medical Officer for Selecta Biosciences (2015-2019), Targacept (2014-2015) and Plasma Surgical (2013-2014). From 2011 to 2013, he was a consultant to biotechnology, pharmaceutical, and health care companies, leading protocol development and execution for Phase 1-4 studies in areas including women’s and men’s health, oncology, neuroscience and gastroenterology. From 2003 to 2011, Dr Sands was with Solvay Pharmaceuticals/Abbott Laboratories (following its acquisition of Solvay) in a series of roles of increasing responsibility culminating as Executive Vice President, Market Access and Senior Vice President of Research and Development. Earlier in his career, he worked with Procter & Gamble Pharmaceuticals,

founded a medical education company, and was a managing partner in a medical practice. He earned his Medical Doctor Degree from Hahnemann University School of Medicine in Philadelphia, PA, and has completed courses in the Executive MBA program at Emory University in Atlanta, GA.

In this podcast, Conference Producer, Andrew Goldstein, reviews what to expect at the 9th annual Chief Medical Officer Summit 360°. The conference will take place October 14-15, 2021 in Boston, MA also with virtual attendance options. 

Learn more about the conference taking place October 14-15, 2021 at theconferenceforum.org

In this podcast, first presented at the PODD: Partnership Opportunities in Drug Delivery 2020 conference, you will hear Dr Barbara Lueckel, Roche Pharma Partnering provide her annual review on the drug delivery industry including notable highlights and partnerships that occurred over the past ten years.

To learn more about the 2021 PODD: Partnership Opportunities in Drug Delivery conference please visit www.poddconference.com

In this podcast, Conference producer, Mark Scherzer, reviews what to expect at the 8th annual Mobile in Clinical Trials conference. The conference will take place September 27, 2021 in Boston, MA also with virtual attendance options. Learn more here.

In this podcast, Valerie Bowling, Director of the PODD Drug Delivery conference gives a run down summarizing what is being featured at the 11th annual event. 

Learn more about the conference taking place October 28-29, 2021 at poddconference.com